Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Biopharma Holdings, Inc.

We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.

Oxford Finance LLC

Silicon Valley Bank

Armistice Capital

Deerfield

Asahi Kasei

Palmetto Partners

Bay City Capital

Wild Basin Investments

Merieux Developpement

Xeris Pharmaceuticals, Inc.

Wishing health, happiness, and prosperity to all celebrating the Lunar New Year! 
 
As many welcome the Year of the Dragon this week with hopes for a lucky year ahead, we at Xeris join in honoring the occasion. May it bring new beginnings filled with joy.
 
The values of compassion, care and community at the heart of this holiday inspire us daily in our mission. However you mark this festive time of renewal, we wish you the very best in the year to come.

#LunarNewYear #LunarNewYear2024 #YearOfTheDragon

Meet Emily, one of our Cushing’s Syndrome Patient Voices. In 2015, Emily’s diagnosis of Cushing’s came a year and a half after scans showed benign tumors on both of her adrenal glands. Her original endocrinologist did not look for Cushing’s, and it was not until she saw a new endocrinologist that her Cushing’s was diagnosed.

Although Emily does not look like other individuals who live with Cushing’s— for example, she is not overweight — an endocrinologist she saw for a routine follow-up check on her adrenal tumors noticed her cortisol was elevated and sent her to a Cushing’s specialist. That endocrinologist diagnosed Cushing’s.
 
Unfortunately, delay in diagnosis is far too common for many individuals living with a rare disease. Emily's advice to others living with Cushing's is to "remember that Cushing’s can look different in different people and remain compassionate — for yourself and others.”

We take pride in supporting #RareDiseaseMonth this February to raise awareness for those living with Cushing's and supporting those who treat it. We understand Cushing's is not a "one size fits all approach."

Connect with us through Xeris CareConnection™ to speak with a Patient Access Manager and learn more about Emily's story. Click here to sign up for support: https://lnkd.in/gPXvi5ZC
 
#Cushings #CushingDisease #CushingsSyndrome #RareDisease

We are so excited to be exhibiting at #PriMedSouth in Fort Lauderdale later this week! Visit Booth #322 to learn about the importance of having a safety net if you or a loved one is at risk for very low blood sugar. If you’re attending, let us know in the comments! 

Pri-Med

We are so honored to have our Gvoke HypoPen® influencer campaign chosen out of over 2,000 entries as both a Bronze Anthem Winner and a Community Voice Award Winner in the Social Media Content, Campaign or Channel category. Thank you to The Anthem Awards for recognizing the importance of equipping diabetes patients with a safety net to treat very low blood sugar. 
 
Check out our call to action here: https://lnkd.in/gPT9r2Qc and learn more about Gvoke HypoPen® (glucagon injection) at https://lnkd.in/gJX_xGiu.

#AnthemAwards #Diabetes #DiabetesAwareness #DiabetesCommunity #InfluencerMarketing #GvokeHypoPen

What is GVOKE? GVOKE is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 2 years and above. It is not known if GVOKE is safe and effective in children under 2 years of age.

Do not use GVOKE if: you have a tumor in the gland on top of your kidneys (adrenal gland) called a pheochromocytoma, as it may cause a substantial increase in blood pressure; you have a tumor in your pancreas called an insulinoma, as it may cause low blood sugar; or if you are allergic to glucagon or any inactive ingredient in GVOKE.

GVOKE may cause other serious side effects, such as Serious skin rash -- in certain people with a tumor in their pancreas called a glucagonoma; Serious allergic reactions -- Call your doctor or get medical help right away if you have a serious allergic reaction including rash, difficulty breathing, low blood pressure.

See Important Safety Information: https://lnkd.in/gA79wrqT
 
See Full Prescribing Information: https://bit.ly/3baHqAO

Meet Jodi, one of our Cushing’s Syndrome Patient Voices. For Jodi, receiving a Cushing's diagnosis was validating because she had always believed her Cushing's-related symptoms were not her fault. A diagnosis proved to her that she was not to be blamed for her symptoms. 
 
As we shine a light on our patient voices throughout #RareDiseaseMonth, we encourage those living with a rare disease to always advocate for themselves just like Jodi has. We take pride in supporting Rare Disease Month this February to raise awareness for those living with Cushing’s and supporting those who treat it. Connect with us through Xeris CareConnection™ to speak with a Patient Access Manager and learn more about Jodi's story. Click here to sign up for support: https://lnkd.in/gPXvi5ZC
 
#Cushings #CushingDisease #CushingsSyndrome #RareDisease

Join clinical experts  David Lieb, MD, FACE, Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, and Vin Tangpricha, MD, PhD, FACE as they discuss the 2022 AACE diabetes guideline updates and address the issue, “How Should Hypoglycemia Be Managed? Listen to the podcast today!

Are you looking for a rewarding new opportunity?

We're #hiring two Area Business Specialists to join the Xeris team!

To learn more and apply, visit https://bit.ly/499XFcU

#PharmaJobs #RareDiseases

Today, we join millions nationwide in remembrance of civil rights leader Dr. Martin Luther King Jr. His leadership and advocacy during the Civil Rights Movement led to monumental societal shifts that continue to pave the way for equality.
 
Dr. King organized peaceful demonstrations and delivered legendary speeches like "I Have a Dream" to galvanize support to end segregation and secure voting rights for all. His nonviolent resistance and call for people of all races, religions and backgrounds to unite in fellowship deeply impacted the conscience of America. 
 
Even with major milestones accomplished, Dr. King's dream remains unfinished. As we pause to honor his courage, we also recommit ourselves to enacting change. At Xeris, this means fostering a diverse, equitable and inclusive culture where all our employees feel welcomed, valued and empowered. We strive to incorporate Dr. King's values of compassion and human dignity into every aspect of our work.
 
We hope Dr. King's extraordinary message resonates with all our connections near and far.

#MLKDay #MartinLutherKingJr

If you're interested in working in the #diabetes space, we're hiring for Territory Business Representatives, Diabetes in Atlanta West, Omaha, Tulsa, and Central Georgia. Apply now! https://lnkd.in/gt82PnVe

#DiabetesCommunity #Hiring

Exciting news! Today we announced that Xeris has entered into an exclusive worldwide license agreement for Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab (known as TEPEZZA® in the United States) using our XeriJect® technology in Thyroid Eye Disease (TED) - a serious, progressive and potentially vision-threatening rare autoimmune disease. 

Read more: https://lnkd.in/gPcdGCVZ 

#ThyroidEyeDisease #PharmaNews #Pharmaceuticals

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-13.21M -	-26.55M 101.03%	-60.08M 126.26%	-91.14M 51.70%	-122.72M 34.66%	-94.66M 22.87%	-94.66M 0%	-62.26M 34.23%
depreciation and amortization	116K -	177K 52.59%	320K 80.79%	1.47M 358.44%	1.88M 28.08%	12.67M 574.19%	12.67M 0%	13.16M 3.88%
deferred income tax			-414K -	536K 229.47%	1.11M 108.02%	-1.42M 227.71%	-1.42M 0%	-1.25M 12.29%
stock based compensation	540K -	499K 7.59%	1.73M 246.29%	8.27M 378.76%	11.38M 37.57%	12.16M 6.84%	12.16M 0%	10.72M 11.88%
change in working capital	-3.58M -	1.12M 131.29%	1.61M 43.35%	-2.80M 274.11%	11.85M 523.66%	-35.15M 396.52%	-35.15M 0%	-6.29M 82.09%
accounts receivables	204K -	-1.10M 638.24%	-1.67M 52.09%	-2.18M 30.66%	-6.24M 185.84%	-13.37M 114.43%	-13.37M 0%	-8.37M 37.44%
inventory	-846K -	1.70M 300.71%	4.04M 138.04%	-5.14M 227.24%	-7.42M 44.23%	-7.46M 0.63%	-7.46M 0%	-14.80M 98.31%
accounts payables	-2.91M -	661K 122.72%	-1.11M 267.93%	-2.49M 123.96%	5.53M 322.33%	-4.32M 178.13%	-4.32M 0%	6.96M 261.16%
other working capital	-32K -	-140K 337.50%	345K 346.43%	7.01M 1,932.75%	19.98M 184.93%	-9.99M 150.01%	-9.99M 0%	9.92M 199.25%
other non cash items	49K -	94K 91.84%	560K 495.74%	3.10M 454.29%	961K 69.04%	3.52M 265.76%	3.52M 0%	-2.29M 165.04%
net cash provided by operating activities	-16.09M -	-24.66M 53.31%	-56.28M 128.19%	-80.56M 43.14%	-95.53M 18.59%	-102.89M 7.70%	-102.89M 0%	-48.21M 53.15%
investments in property plant and equipment	-35K -	-700K 1,900%	-1.51M 115.71%	-377K 75.03%	-1.08M 187.80%	-524K 51.71%	-524K 0%	-2.26M 331.87%
acquisitions net				377K -	38.47M 10,103.98%	38.47M 0%
purchases of investments			-68.85M -	-101.77M 47.82%	-43.02M 57.73%	-43.02M 0%		-43.74M -
sales maturities of investments			2.10M -	74.75M 3,459.29%	103.60M 38.60%	34.98M 66.23%	34.98M 0%	40M 14.33%
other investing activites				-377K -		4.55M -
net cash used for investing activites	-35K -	-700K 1,900%	-68.26M 9,651.57%	-27.41M 59.85%	97.96M 457.47%	34.46M 64.82%	34.46M 0%	-6.00M 117.42%
debt repayment	-32K -			-25.09M -	-25.09M 0%	-43.50M 73.37%	-43.50M 0%
common stock issued			98.33M -	65.89M 32.99%	27M 59.02%	30M 11.11%	30M 0%	581K 98.06%
common stock repurchased				-63K -	-534K 747.62%	-468K 12.36%	-468K 0%	-1.01M 115.60%
dividends paid				-95.64M -	-25.09M 73.77%		-147.05M -
other financing activites	3.94M -	35.14M 792.76%	29.89M 14.95%	180.97M 505.53%	50.96M 71.84%	141.44M 177.55%	288.49M 103.97%	-1 100.00%
net cash used provided by financing activities	3.90M -	35.14M 800.08%	128.21M 264.87%	126.06M 1.67%	27.25M 78.39%	127.47M 367.84%	127.47M 0%	-428K 100.34%
effect of forex changes on cash				-22K -	-3K 86.36%	-3K 0%		123K -
net change in cash	-12.22M -	9.78M 180.01%	3.67M 62.45%	18.08M 392.48%	29.67M 64.13%	59.04M 98.98%	59.04M 0%	-54.52M 192.33%
cash at beginning of period	44.49M -	32.27M 27.46%	42.05M 30.30%	19.52M 53.58%	37.60M 92.62%	67.27M 78.92%	67.27M 0%	121.97M 81.31%
cash at end of period	32.27M -	42.05M 30.30%	45.72M 8.73%	37.60M 17.76%	67.27M 78.92%	126.31M 87.77%	126.31M 0%	67.45M 46.60%
operating cash flow	-16.09M -	-24.66M 53.31%	-56.28M 128.19%	-80.56M 43.14%	-95.53M 18.59%	-102.89M 7.70%	-102.89M 0%	-48.21M 53.15%
capital expenditure	-35K -	-700K 1,900%	-1.51M 115.71%	-377K 75.03%	-1.08M 187.80%	-524K 51.71%	-524K 0%	-2.26M 331.87%
free cash flow	-16.12M -	-25.36M 57.32%	-57.79M 127.85%	-80.94M 40.05%	-96.62M 19.38%	-103.42M 7.03%	-103.42M 0%	-50.47M 51.20%

NASDAQ:XERS

Xeris Biopharma Holdings, Inc.

Last Close

2.02

17/05 20:00

Market Cap

343.93M

Beta: -

Volume Today

1.24M

Avg: 1.25M

PE Ratio

−4.97

PFCF: −4.75